BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

819 results

Results per page: 10 20 30

Information Letter on Velcade® 1 mg powder for solution for injection (bortezomib) : Discontinuation of supply due to production difficulties PDF, 97KB, File is accessible Date: 21. November 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: bortezomib

The pharmaceutical manufacturer issues information on the discontinuation of supply of Velcade® 1 mg powder for solution for injection due to production difficulties on the part of the contract manufacturer.

Rote-Hand-Brief on Supertendin® PDF, 199KB, File is accessible Date: 17. November 2011 Topics: Pharmakovigilanz Type: Download

Active substance: dexamethasone

Dear Doctor Letter (Rote-Hand-Brief) on Supertendin® 5 ampoules: Batch recall due to a quality defect PDF, 199KB, File is accessible Date: 17. November 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dexamethasone

The pharmaceutical manufacturer issues new information on the pharmacy and physician level recall of certain batches of Supertendin® 5 ampoules based on a quality defect.

Rote-Hand-Brief on Cipramil® PDF, 147KB, File is accessible Date: 31. October 2011 Topics: Pharmakovigilanz Type: Download

Active substance: citalopram

Dear Doctor Letter (Rote-Hand-Brief) on Cipramil® (citalopram): Risk of dose-dependent QT interval prolongation PDF, 147KB, File is accessible Date: 31. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: citalopram

Important information on the risk of dose-dependent prolongations of the QT interval as well as on altered recommendations as to the maximum dose.

These new scientific findings also apply to all generic marketing authorisations of …

Rote-Hand-Brief on Supertendin® PDF, 237KB, File is accessible Date: 27. October 2011 Topics: Pharmakovigilanz Type: Download

Active substance: dexamethasone

Rote-Hand-Brief on Pradaxa® PDF, 428KB, File is accessible Date: 27. October 2011 Topics: Pharmakovigilanz Type: Download

Active substance: dabigatran etexilate

Dear Doctor Letter (Rote-Hand-Brief) on Pradaxa® (dabigatran etexilate): Necessity of monitoring renal function PDF, 428KB, File is accessible Date: 27. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dabigatran etexilate

Summaries of Product Characteristics and reference material for physicians extended to include information on the necessity of determining the creatinine clearance prior to beginning treatment as well as of further control of renal function.

Dear Doctor Letter (Rote-Hand-Brief) on Supertendin® 5 ampoules: Batch recall due to a quality defect PDF, 237KB, File is accessible Date: 27. October 2011 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dexamethasone

The pharmaceutical manufacturer issues information on the pharmacy and physician level recall of certain batches of Supertendin® 5 ampoules based on a quality defect.

Rote-Hand-Brief on Advagraf® PDF, 299KB, File is accessible Date: 21. October 2011 Topics: Pharmakovigilanz Type: Download

active substance: tacrolimus